Our approach
Watch this three-minute video to hear David Cumming, Chief Investment Officer, Equities, explain the benefits of being active investors without style constraint in today's climate, how we integrate environmental, social and governance (ESG) considerations in to our investment approach and what he believes makes us different.
Active, fundamental and responsible
Our integrated and disciplined investment process provides the framework and confidence for portfolios to have high active shares. We use our access to management to gain an information advantage, driving non-consensus views. We direct our resource towards fundamental analysis and being on the right side of change – an option not available to passives or ETFs.
ESG is a core, integrated input into our investment process. We actively assess individual company ESG performance and risk factors. In conjunction with our Global Responsible Investment (GRI) team we continually engage with companies to promote positive change and monitor the long-term value of our investments.
Benefits
Our investment advantage.
Connected thinking
A common investment language embedded across all regions and sectors facilitates the delivery of sharp and effective connected thinking. Enhanced by direct company contact and integrated information flows from ESG, Macro, Multi-Asset and Credit teams, our process ensures all relevant investment information is surfaced when making each stock selection decision.
Key risks
For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.
The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency and exchange rates. Investors may not get back the original amount invested.
Strategies in focus
A globally integrated team with extensive experience
David Cumming
Chief Investment Officer, Equities and Head of UK Equities
Read bio
Mikhail Zverev
Head of Global Equities
Read bio
Susan Schmidt
Head of US Equities
Read bio
Frédéric Tassin
Head of Pan-European Equities
Read bio
Francois de Bruin
Fund Manager, Sustainable Income & Growth and Head of Listed Real Estate
Read bio
Alistair Way
Head of Global Emerging Market Equities
Read bio
Need more information?
For further information, please contact our investment sales team.
Equities views
Equities and COVID-19: Now is not the time to double-down on uncertainty
21 May 2020
As the effects of COVID-19 continue to rip through societies and economies, Trevor Green explains why adding uncertainty on top of uncertainty is never a good investment strategy. He outlines three critical, but simple, rules for navigating the current equity market.
Read more
COVID-19: The impact on global equities
28 Apr 2020
As the coronavirus pandemic wreaks havoc on global economies, Giles Parkinson assesses the impact across equity markets and the longer-term implications for investors.
Read more
Size matters: Will COVID-19 lead to a concentration of corporate power?
22 Apr 2020
The fallout from the coronavirus pandemic could see large firms cement their dominance over weaker rivals. We examine the implications for investors.
Read more
Are investors too complacent about the coronavirus?
21 Feb 2020
In the latest of our editorial series, Link, AIQ brings members of Aviva Investors’ investment strategy, equity and debt teams together to discuss the prospects for financial markets and the world economy in the face of the coronavirus epidemic.
Read more
Cwtch: Has capitalism gone cuddly?
18 Feb 2020
In the first of a new editorial series, Link, AIQ brings together people from across Aviva Investors to debate topical themes. Mirza Baig and Stephanie Niven consider whether CEO claims about running businesses for multiple stakeholders rather than shareholders alone is a grand idea or just plain grandstanding.
Read more
Multi-asset allocation views: Why the bull run in global equities could continue
12 Feb 2020
Sunil Krishnan discusses the conditions for a continued rise in global equities, the potential of Japanese and US equities to outperform from a regional perspective, and some attractive features of emerging markets – particularly Brazil – which may have been overlooked.
Read more
Dealing with climate change: A mixture of mitigation and adaptation
4 Dec 2019
The asset management industry has a key role to play in the face of the climate emergency facing humanity. We spoke to Emma Haziza, hydrologist, PhD Mines ParisTech, Founder and President of Mayane, and Rick Stathers, Climate Specialist at Aviva Investors to find out how asset managers can support companies in their climate transition efforts.
Read more
In a complex market, investors need to connect information signals more effectively
19 Nov 2019
A growing body of research suggests equity investors are poor at recognising the connections and interrelationships between companies. A fresh approach is needed, argues Mikhail Zverev, head of global equities at Aviva Investors.
Read more
5G: Anatomy of an equity investment idea
11 Nov 2019
The evolution of wireless technology has fuelled a host of new mobile applications and helped propel companies such as Netflix. 5G, its next iteration, promises speeds up to 20 times faster than the current 4G. But to think only in terms of speed severely underestimates 5G’s potential to fundamentally transform the business landscape – though not without tremendous risk.
Read more
5: Anatomy of an equity investment idea
11 Nov 2019
The evolution of wireless technology has fuelled a host of new mobile applications and helped propel companies such as Netflix. 5G, its next iteration, promises speeds up to 20 times faster than the current 4G. But to think only in terms of speed severely underestimates 5G’s potential to fundamentally transform the business landscape – though not without tremendous risk.
Read more
Back to the future: Dr Eric Topol on AI in healthcare
3 Oct 2019
In the final article in our series on healthcare, we speak to the renowned cardiologist and author Eric Topol about his new book, Deep Medicine.
Read more
Substance over style?
30 Sep 2019
Why an agnostic approach beats equity style biases.
Read more
Big Tech bets on healthcare
25 Sep 2019
In the third of a four-part series on healthcare, we focus on technology. New tech innovations promise to deliver better treatments and cost efficiencies – but concerns over data protection and flawed AI persist.
Read more
Biotech disrupters shake up the drug discovery business
18 Sep 2019
In the second of a four-part series on healthcare, we look at how competition between Big Pharma, Chinese biotech and Silicon Valley is transforming the landscape of drug discovery.
Read more
Investors must hold bad bosses to account
16 Sep 2019
Institutional shareholders need to be as agile and active as private equity in dealing with failures of leadership.
Read more
Medicine, politics and investing: Tensions abound
12 Sep 2019
In the first of a four-part series on global healthcare, we look at why the sector is likely to take centre stage in the 2020 US elections and what this means for investors.
Read more